PTN

PTN 简况

Palatin Technologies, Inc. is a biopharmaceutical company developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCr) system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need. Its MCr system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. The Company’s commercial product Vyleesi (bremelanotide injection), is used for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The Company’s pipeline development programs include PL9643 MCr Agonist for dry eye disease and anti-inflammatory ocular indications, Oral PL8177 for inflammatory bowel diseases, and Melanocortin peptides for diabetic retinopathy. Its product development activities in inflammation disease indications focus on development of MCr peptides for ocular conditions, as well as conditions in the gut and kidney.